August 2026 FDA oncology updates: iberdomide, zanidatamab and daraxonrasib win approvals as fast-track designations ...
The FDA has approved ropeginterferon alfa-2b-njft (Besremi) for adults with essential thrombocythemia (ET), marking the first ...
ASCO's updated guideline on breast cancer follow-up recommends risk-based surveillance intensity and selective mammography ...
The FDA has approved rusfertide (Mimrylo) for adult patients with polycythemia vera (PV). 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results